News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG issues convertible bonds

PDF Berlin (Germany) and Germantown, MD (U.S.A.), September 8, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced that it has issued convertible bonds with a nominal value of EUR 7.1 million to Cathay Fortune International Company Limited (CFIC) excluding pre-emptive rights of existing shareholders. The issuance of the convertible bonds, […]

Read more

Epigenomics Commences Post Approval Study on Epi proColon®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), August 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT) – NCT03218423. The PERT trial is being conducted in concert with the US […]

Read more

Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results

PDF -Reimbursement in the United States is a focus of the company as it will have the greatest impact upon commercial adoption of Epi proColon -The expected issuance of the convertible bond as agreed in the voluntary takeover offer will improve the financial position of the company with the addition of approximately EUR 6.5 million […]

Read more

Epigenomics AG: Voluntary public takeover offer by Summit Hero Holding not successful

PDF Berlin, July 12, 2017 – Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, […]

Read more

Epigenomics AG: Executive Board and Supervisory Board recommend acceptance of the voluntary public takeover offer

PDF Berlin, 14 June 2017 – The Executive Board and Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) have evaluated the voluntary public takeover offer of Summit Hero Holding GmbH (“Bidder”) and have published their statement pursuant to section 27 of the German Takeover Act (Wertpapiererwerbs- und Übernahmeangebot ‑ WpÜG). The Executive Board […]

Read more

Offer document published for the voluntary public takeover offer for Epigenomics AG

PDF Berlin, 8 June 2017 – Today Summit Hero Holding GmbH published the offer document for the voluntary takeover offer for all outstanding shares of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY). This marks the beginning of the acceptance period, in which Epigenomics shareholders can accept the cash offer of 7.52 Euros per share. […]

Read more
...